S. ChristianPlatt

Partner

San Diego + 1.858.314.1156 Silicon Valley + 1.650.687.4175

Connect:

Share

As a seasoned trial lawyer with more than 25 years of experience, Christian Platt handles complicated intellectual property disputes in the courts, arbitral tribunals, and the U.S. Patent Office, including patent infringement, patent validity, trade secret, and licensing disputes. He routinely tries cases before judges and juries, including a first-chair three-week patent trial win resulting in a jury verdict of noninfringement selected by The Daily Journal as a "Top Defense Result" of the year.

Christian represents leading life sciences companies in their most complex patent disputes, including patents covering gene therapy, cell therapy, gene editing, antibodies, plasmids, cell lines, proteomics, liquid biopsy, vaccines, vaccine delivery mechanisms, pharmaceuticals, and transgenic animal models. Christian also handles other technologies, including medical devices, telecommunications, video games, consumer electronics, computer hardware, software, and networking technologies.

Christian has been recognized by numerous legal publications, including The Legal 500 US, where clients describe him as "very professional" who does "a great job presenting [a] case." He has written and spoken extensively on litigation strategy and patent damages. He authored a chapter in Life Sciences Client Strategies (Aspatore, 2007) after the editorial board of Inside the Minds selected him as a leader in intellectual property life sciences law.

Christian has held leadership positions in the American Bar Association Intellectual Property Law Section, including chairing the Patent Litigation and Post-Grant and IPR Committees. He has served on the Board of Governors of the Association of Business Trial Lawyers and is an active member of the American Intellectual Property Law Association (AIPLA).

Experience

  • REGENXBIO resolves patent dispute with Aldevron over patented host cells used in gene therapy applicationsJones Day represented plaintiff REGENXBIO Inc. in a patent infringement case brought against Aldevron LLC claiming that without authorization, Aldevron used and manufactured cultured host cells containing recombinant nucleic acid molecules with sequences encoding AAV8 capsid protein(s) and a heterologous non-AAV sequence.
  • Kyowa Hakko Kirin and BioWa successfully enforce patent rights on antibody technologyJones Day, on behalf of Japanese life sciences company Kyowa Hakko Kirin Company, Limited ("KHK") and its wholly-owned U.S. subsidiary, BioWa, successfully settled a patent infringement suit over three of KHK's patents that underlie KHK's award-winning POTELLIGENT® technology capable of producing therapeutic antibodies with dramatically improved potency and efficacy.
  • Kyowa Hakko Kirin defeats competitors in Patent Trial and Appeal Board challenge of patents on antibody technologyOn October 23, 2017, the Patent Trial and Appeal Board ("PTAB") issued a trio of decisions, unanimously declining to institute inter partes review ("IPR") of three patents owned by a Japanese pharmaceutical company represented by Jones Day, Kyowa Hakko Kirin Co., Ltd.
  • REGENXBIO successfully blocks institution of post-grant review of gene therapy patentJones Day successfully defended REGENXBIO, Inc. against a post-grant review (PGR) petition filed by Passage Bio before the U.S. Patent Trial and Appeal Board (PTAB) against one of REGENXBIO's AAV9 patents.
  • AbbVie successfully defends HUMIRA® formulation patent against four IPR petitions filed by CoherusJones Day served as lead counsel and successfully defended AbbVie in connection with four (4) separate inter partes review (IPR) petitions brought by Coherus Biosciences, Inc. against U.S. Patent No. 9,085,619, which is related to formulations for AbbVie's antibody adalimumab, marketed as HUMIRA®.
  • St. Jude and Juno secure $12.25 million settlement resolving patent dispute with Novartis Pharmaceuticals and University of PennsylvaniaJones Day represented St. Jude Children's Research Hospital ("St. Jude") in enforcing breach of contract claims and defending patent invalidity claims against the University of Pennsylvania ("Penn") and Novartis Pharmaceuticals ("Novartis").
  • CJ CheilJedang defends German patent infringement action by Japanese competitorJones Day represented CJ CheilJedang Corporation, a major Korean-based multinational company, in an international patent dispute with a Japanese competitor before the courts in Germany, including the Federal Supreme Court of Germany.
  • Allergan defends JUVEDERM® patents against nine IPR petitions filed by ProlleniumJones Day is representing Allergan, Inc. before the U.S. Patent Trial and Appeal Board ("PTAB") on nine IPR petitions filed by Prollenium challenging multiple patents covering certain of Allergan's JUVEDERM® products, hyaluronic acid-based dermal fillers that include the anesthetic lidocaine.
  • PI Advanced Materials obtains CAFC affirmance of summary judgment win in patent case regarding polyimide filmsJones Day successfully obtained a Federal Circuit affirmance of a summary judgment win of non-infringement on behalf of PI Advanced Materials Co., Ltd. ("PIAM", formerly SKC Kolon PI, Inc. ("SKPI")).
  • SOLiD and Reach obtain jury verdict finding non-infringement in competitor-vs.-competitor patent caseFollowing a seven day trial, a jury in the Northern District of California unanimously found that Jones Day clients SOLiD, Inc. and Reach Holdings LLC did not infringe any claims of a 16-year-old wireless communications patent owned by Corning Optical Communications Wireless Ltd., a subsidiary of Corning, Inc.
  • Qualcomm resolves worldwide Chinese litigationJones Day represented Qualcomm Incorporated as complainant in an ITC action against a Chinese phone manufacturer and several distributors asserting five patents concerning radio frequency transceivers, device structures, packaging, structures, and camera phone operation.
  • CORSAIR® acquires SCUF Gaming®Jones Day advised CORSAIR® in connection with the acquisition and related financing of high-performance controller pioneer SCUF Gaming "SCUF®" and its extensive patent portfolio.
  • Japanese wire manufacturer and its U.S. subsidiary defend against alleged patent infringement regarding wire technologyJones Day secured a final judgment of non-infringement and invalidity in favor of a Japanese wire manufacturer and its U.S. subsidiary in a patent infringement case related to coil wire technology in the Central District of California.
  • Kakao obtains dismissal of patent infringement action relating to teleconferencing technologyAfter filing a motion to dismiss for lack of personal jurisdiction for Korea-based Kakao Corporation in a patent infringement action involving two patents relating to teleconferencing technology, Jones Day obtained dismissal of the action with prejudice.
  • Kakao patent infringement action relating to voice messaging technology successfully dismissedJones Day successfully defended Kakao Corporation in a patent infringement action involving five patents relating to voice messaging technology.
    • View All

    July 2024 Alert

    USPTO Requests Comments on the Experimental Use Exception

    May 2024 Commentary

    Canadian Drug Importation May Undermine Intellectual Property Protection

    December 2020 Blog

    PTAB Touts Soaring MTA Pilot Program, PTAB Litigation Blog

    October 2019 Blog

    PTAB Proposes Burden of Persuasion Rules for AIA Amendments, PTAB Litigation Blog

    February 2019 Blog

    No PTAB Do Over: After SAS Remand, PTAB Denies All Grounds, PTAB Litigation Blog

    February 2019 Blog

    E-Trading Patents Are "For Technological Inventions," Not Subject To CBM Review, PTAB Litigation Blog

    February 2019 Commentary

    Supernus: Federal Circuit Provides Clarity on USPTO Discretion on Patent-Term Adjustment Calculations

    November 2018 Blog

    PTAB Flushes Airplane Lavatory Patent On On-Sale Bar, PTAB Litigation Blog

    September 2018 Blog

    PTAB/TTAB Hearings May Be Coming To A Law School Near You, PTAB Litigation Blog

    August 2018 Blog

    Practical Tips from the Judges’ Panel at the PTAB Judicial Conference, PTAB Litigation Blog
    View All

    Additional Publications

    Publications Prior to Jones Day

    August 13, 2013

    Recent Trends and Approaches in Calculating Patent Damages: Nash Bargaining Solution and Conjoint Surveys, Patent, Trademark & Copyright Journal (BNA)

    September 20, 2011

    Obtaining Preliminary Injunctions in Open-Source Cases, Intellectual Property Litigation, American Bar Association Section of Litigation: Intellectual Property

    February 2, 2011

    Subject Matter Patentability and the Biotech Industry, AIPLA Mid-Winter Institute

    June 1, 2011

    Proving Patent Damages after Uniloc, Proof, American Bar Association Trial Evidence Committee

    April 30, 2010

    The Rise and Fall of Patent Marking Suits, Patent, Trademark & Copyright Journal (BNA)

    August 31, 2009

    Preparing for and Defending Against Claims of Corporate Officer Personal Liability for Patent Infringement, Bloomberg Law Reports

    December 15, 2008

    In-House Open Source Compliance Programs Should Be Considered in Wake of Jacobsen decision, Bloomberg Intellectual Property Law Report

    January 31, 2008

    Recently Renewed Patent Reform Act’s Impact on Medical Device Industry, San Diego Daily Transcript

    2008

    Inside the Minds: Life Sciences Client Strategies, Aspatore Books

    2007

    The Great Unknown: Advice for New Law Firm Partners, The Recorder

    Winter 2007

    Beware Foreign Defendants: You May Be Liable For Patent Infringement Even Without Conducting Any Business in the United States, New Matter, State Bar of California

    December 8, 2006

    Doubting the Obvious, Los Angeles Daily Journal

    October 2006

    Choosing Your Turf: A Brief Overview of Venue in Patent Cases, Intellectual Property Today

    Additional Speaking Engagements

    • April 13, 2021
      Navigating Patent Damages, 2021 American Bar Association Intellectual Property Law Spring Meeting
    • January 28, 2016
      Winning Strategies for Litigating Patent Trials, Northern California Jones Day University
    • February 25, 2015
      Practical Strategies for Addressing the Evolving Patent-Damages Landscape, Federal Bar Association
    • January 15, 2015
      2014 Patent Law Year in Review (and a Look Ahead at 2015)
    • September 30, 2014
      Winning Trial Techniques for the Complex Patent Litigator, 2014 Patent Disputes Forum
    • September 26, 2014
      IP Enforcement in the US: the Jury Trial, Asia Intellectual Property Finance and Business Conference
    • September 22, 2014
      Deposition and Trial Strategies for Witnesses in United States Lawsuits, In-House Counsel Forum

    Speaking Engagements Prior to Jones Day

    October 24, 2013

    Recent Developments regarding Patent Damages, Patent Litigation Committee, AIPLA Annual Meeting

    Washington, D.C.

    April 3, 2013

    How to Prove Damages in Patent, Trademark and Copyright Cases, The Knowledge Conference 

    Webinar

    February 2, 2011

    Subject Matter Patentability and the Biotech Industry, AIPLA Mid-Winter Institute

    Orlando, Florida

    2008

    In-House Open Source Compliance Programs, ACC Roundtable CLE, Association of Corporate Counsel

    San Diego, California

    2006

    How New Patent Rules Make San Diego a More Attractive Patent Litigation Forum for Biotechnology Companies, ACC Roundtable CLE, Association Of Corporate Counsel

    San Diego, California

    2005

    Practical Tips on Enforcing and Defending Patents, American Bar Association Intellectual Property Section Annual Meeting

    San Francisco, California

    2003

    Discovery of Patent Prosecution Documents, American Bar Association Intellectual Property Law Annual Meeting

    Washington, D.C.

    2002

    Effect of Federal Circuit and Supreme Court’s Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd. Opinions, CLE Presentation

    Palo Alto, California

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.